158 related articles for article (PubMed ID: 22535159)
21. [Delayed graft function].
Hertig A
Nephrol Ther; 2008 Oct; 4 Suppl 3():S184-7. PubMed ID: 19000884
[TBL] [Abstract][Full Text] [Related]
22. Clinical evidence on the use of anti-mTOR drugs in renal transplantation.
Hernández D; Martínez D; Gutiérrez E; López V; Gutiérrez C; García P; Cobelo C; Cabello M; Burgos D; Sola E; González-Molina M
Nefrologia; 2011; 31(1):27-34. PubMed ID: 21270910
[TBL] [Abstract][Full Text] [Related]
23. Belatacept: in adult kidney transplant recipients.
Garnock-Jones KP
BioDrugs; 2012 Dec; 26(6):413-24. PubMed ID: 22928660
[TBL] [Abstract][Full Text] [Related]
24. Belatacept.
Prescrire Int; 2012 Jul; 21(129):173-6. PubMed ID: 22852277
[TBL] [Abstract][Full Text] [Related]
25. Profile of belatacept and its potential role in prevention of graft rejection following renal transplantation.
Gupta G; Womer KL
Drug Des Devel Ther; 2010 Dec; 4():375-82. PubMed ID: 21151624
[TBL] [Abstract][Full Text] [Related]
26. [Immunosuppressors].
Sánchez-Fructuoso AI
Nefrologia; 2008; 28 Suppl 5():21-5. PubMed ID: 18847416
[TBL] [Abstract][Full Text] [Related]
27. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT study).
Durrbach A; Pestana JM; Pearson T; Vincenti F; Garcia VD; Campistol J; Rial Mdel C; Florman S; Block A; Di Russo G; Xing J; Garg P; Grinyó J
Am J Transplant; 2010 Mar; 10(3):547-57. PubMed ID: 20415898
[TBL] [Abstract][Full Text] [Related]
28. How the development of new biological agents may help minimize immunosuppression in kidney transplantation: the impact of belatacept.
Wojciechowski D; Vincenti F
Curr Opin Organ Transplant; 2010 Dec; 15(6):697-702. PubMed ID: 20930638
[TBL] [Abstract][Full Text] [Related]
29. Potential of emerging immunosuppressive strategies to improve the posttransplant cardiovascular risk profile.
Djamali A; Pietrangeli CE; Gordon RD; Legendre C
Kidney Int Suppl; 2010 Sep; (118):S15-21. PubMed ID: 20706224
[TBL] [Abstract][Full Text] [Related]
30. Should belatacept be the centrepiece of renal transplantation?
Huber M; Kemmner S; Renders L; Heemann U
Nephrol Dial Transplant; 2016 Dec; 31(12):1995-2002. PubMed ID: 27288461
[TBL] [Abstract][Full Text] [Related]
31. Steroid and calcineurin inhibitor-sparing protocols in kidney transplantation.
Helal I; Chan L
Transplant Proc; 2011 Mar; 43(2):472-7. PubMed ID: 21440737
[TBL] [Abstract][Full Text] [Related]
32. Co-stimulatory blockade with belatacept in kidney transplantation.
Chopra B; Sureshkumar KK
Expert Opin Biol Ther; 2014 May; 14(5):563-7. PubMed ID: 24620724
[TBL] [Abstract][Full Text] [Related]
33. Belatacept: from rational design to clinical application.
Wekerle T; Grinyó JM
Transpl Int; 2012 Feb; 25(2):139-50. PubMed ID: 22151353
[TBL] [Abstract][Full Text] [Related]
34. Use of 12-month renal function and baseline clinical factors to predict long-term graft survival: application to BENEFIT and BENEFIT-EXT trials.
Schnitzler MA; Lentine KL; Axelrod D; Gheorghian A; You M; Kalsekar A; L'Italien G
Transplantation; 2012 Jan; 93(2):172-81. PubMed ID: 22198496
[TBL] [Abstract][Full Text] [Related]
35. Decreased frequency of peripheral CD4(+) CD161(+) Th(17) -precursor cells in kidney transplant recipients on long-term therapy with Belatacept.
Vondran FW; Timrott K; Kollrich S; Klempnauer J; Schwinzer R; Becker T
Transpl Int; 2012 Apr; 25(4):455-63. PubMed ID: 22348376
[TBL] [Abstract][Full Text] [Related]
36. Belatacept in kidney transplantation.
Satyananda V; Shapiro R
Curr Opin Organ Transplant; 2014 Dec; 19(6):573-7. PubMed ID: 25333833
[TBL] [Abstract][Full Text] [Related]
37. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
[TBL] [Abstract][Full Text] [Related]
38. An integrated safety profile analysis of belatacept in kidney transplant recipients.
Grinyó J; Charpentier B; Pestana JM; Vanrenterghem Y; Vincenti F; Reyes-Acevedo R; Apanovitch AM; Gujrathi S; Agarwal M; Thomas D; Larsen CP
Transplantation; 2010 Dec; 90(12):1521-7. PubMed ID: 21088650
[TBL] [Abstract][Full Text] [Related]
39. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression.
Hernández D; Miquel R; Porrini E; Fernández A; González-Posada JM; Hortal L; Checa MD; Rodríguez A; García JJ; Rufino M; Torres A
Transplantation; 2007 Sep; 84(6):706-14. PubMed ID: 17893603
[TBL] [Abstract][Full Text] [Related]
40. Tacrolimus based immunosuppression.
First MR
J Nephrol; 2004; 17 Suppl 8():S25-31. PubMed ID: 15599882
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
